Primary Aldosteronism Prevalence – An Unfolding
                    Story

Suranut Charoensri; Adina F. Turcu

doi:10.1055/a-2066-2696

Experimental and Clinical Endocrinology & Diabetes, Inhaltsverzeichnis

Exp Clin Endocrinol Diabetes 2023; 131(07/08): 394-401
DOI: 10.1055/a-2066-2696

Review

Primary Aldosteronism Prevalence – An Unfolding Story

Suranut Charoensri

¹Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, USA. Ann Arbor, Michigan

²Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine, Khon Kaen University, Thailand

,

Adina F. Turcu

¹Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, USA. Ann Arbor, Michigan

› Institutsangaben

Abstract

Primary aldosteronism (PA) is characterized by dysregulated, renin-independent aldosterone excess. Long perceived as rare, PA has emerged as one of the most common causes of secondary hypertension. Failure to recognize and treat PA results in cardiovascular and renal complications, through processes mediated by both direct target tissue insults and indirectly, by hypertension. PA spans a continuum of dysregulated aldosterone secretion, which is typically recognized in late stages after treatment-resistant hypertension and cardiovascular and/or renal complications develop. Determining the precise disease burden remains challenging due to heterogeneity in testing, arbitrary thresholds, and populations studied. This review summarizes the reports on PA prevalence among the general population and in specific high-risk subgroups, highlighting the impact of rigid versus permissive criteria on PA prevalence perception.

Key words

primary aldosteronism - hypertension - aldosterone - adrenal

Volltext

Referenzen

References
1 Wannachalee T, Lieberman L, Turcu AF. High prevalence of autonomous aldosterone production in hypertension: How to identify and treat it. Curr Hypertens Rep 2022; 24: 123-132
2 Monticone S, D’Ascenzo F, Moretti C. et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: A systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018; 6: 41-50
3 Hundemer GL, Curhan GC, Yozamp N. et al. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: A retrospective cohort study. Lancet Diabetes Endocrinol 2018; 6: 51-59
4 Mulatero P, Monticone S, Bertello C. et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab 2013; 98: 4826-4833
5 Salcuni AS, Carnevale V, Battista C. et al. Primary aldosteronism as a cause of secondary osteoporosis. Eur J Endocrinol 2017; 177: 431-437
6 Reincke M, Rump LC, Quinkler M. et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab 2009; 94: 869-875
7 Sechi LA, Novello M, Lapenna R. et al. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295: 2638-2645
8 Wu V-C, Wang S-M, Huang K-H. et al. Long-term mortality and cardiovascular events in patients with unilateral primary aldosteronism after targeted treatments. Eur J Endocrinol 2021; 186: 195-205
9 Rossi GP, Maiolino G, Flego A. et al. Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term. Hypertension 2018; 71: 585-591
10 Chen Y-Y, Lin Y-HH, Huang W-C. et al. Adrenalectomy improves the long-term risk of end-stage renal disease and mortality of primary aldosteronism. J Endocr Soc 2019; 3: 1110-1126
11 Hundemer GL, Curhan GC, Yozamp N. et al. Renal outcomes in medically and surgically treated primary aldosteronism. Hypertension 2018; 72: 658-666
12 Funder JW, Carey RM, Mantero F. et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
13 Huang W-C, Lin Y-H, Wu V-C. et al. Who should be screened for primary aldosteronism? A comprehensive review of current evidence. J Clin Hypertens (Greenwich) 2022; 24: 1194-1203
14 Zekarias K, Tessier KM. Screening rate for primary aldosteronism among patients with apparent treatment-resistant hypertension: Retrospective analysis of current practice. Endocr Pract 2022; 28: 271-275
15 Hundemer GL, Kline GA, Leung AA. How common is primary aldosteronism?. Curr Opin Nephrol Hypertens 2021; 30: 353-360
16 Jaffe G, Gray Z, Krishnan G. et al. Screening rates for primary aldosteronism in resistant hypertension: A cohort study. Hypertension 2020; 75: 650-659
17 Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17
18 Conn JW. Evolution of primary aldosteronism as a highly specific clinical entity. J Am Med Assoc 1960; 172: 1650-1653
19 Conn JW. Plasma renin activity in primary aldosteronism. Importance in differential diagnosis and in research of essential hypertension. JAMA 1964; 190: 222-225
20 Conn JW, Rovner DR, Cohen EL. Normal and altered function of the renin-angiotensin-aldosterone system in man: Applications in clinical and research medicine. Ann Intern Med 1965; 63: 266-284
21 Channick BJ, Adlin EV, Marks AD. Suppressed plasma renin activity in hypertension. Arch Intern Med 1969; 123: 131-140
22 Grim CE. Editorial: Low renin "essential’’ hypertension; a variant of classic primary aldosteronism?. Arch Intern Med 1975; 135: 347-350
23 Padfield PL, Brown JJ, Lever AF. et al. Is low-renin hypertension a stage in the development of essential hypertension or a diagnostic entity?. Lancet 1975; 1: 548-550
24 Adlin EV. Letter: Plasma-renin and blood-pressure. Lancet 1975; 1: 699
25 Hiramatsu K, Yamada T, Yukimura Y. et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med 1981; 141: 1589-1593
26 Vaidya A, Mulatero P, Baudrand R. et al. The expanding spectrum of primary aldosteronism: Implications for diagnosis, pathogenesis, and treatment. Endocr Rev 2018; 39: 1057-1088
27 Monticone S, Burrello J, Tizzani D. et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017; 69: 1811-1820
28 Stowasser M, Ahmed AH, Pimenta E. et al. Factors affecting the aldosterone/renin ratio. Horm Metab Res 2012; 44: 170-176
29 Baudrand R, Guarda FJ, Torrey J. et al. Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism. J Clin Endocrinol Metab 2016; 101: 3989-3996
30 Ariens J, Horvath AR, Yang J. et al. Performance of the aldosterone-to-renin ratio as a screening test for primary aldosteronism in primary care. Endocrine 2022; 77: 11-20
31 Hung A, Ahmed S, Gupta A. et al. Performance of the aldosterone to renin ratio as a screening test for primary aldosteronism. J Clin Endocrinol Metab 2021; 106: 2423-2435
32 Ng E, Gwini SM, Libianto R. et al. Aldosterone, renin, and aldosterone-to-renin ratio variability in screening for primary aldosteronism. J Clin Endocrinol Metab 2022; 108: 33-41
33 Maciel AAW, Freitas TC, Fagundes GFC. et al. Intraindividual variability of serum aldosterone and its implication for primary aldosteronism screening. J Clin Endocrinol Metab 2022; dgac679
34 Yozamp N, Hundemer GL, Moussa M. et al. Intraindividual variability of aldosterone concentrations in primary aldosteronism: Implications for case detection. Hypertension 2021; 77: 891-899
35 Markou A, Pappa T, Kaltsas G. et al. Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: A very high odds ratio for progression into arterial hypertension. J Clin Endocrinol Metab 2013; 98: 1409-1416
36 Brown JM, Siddiqui M, Calhoun DA. et al. The unrecognized prevalence of primary aldosteronism: A cross-sectional study. Ann Intern Med 2020; 173: 10-20
37 Käyser SC, Dekkers T, Groenewoud HJ. et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: A systematic review and meta-regression analysis. J Clin Endocrinol Metab 2016; 101: 2826-2835
38 Vaidya A, Malchoff CD, Auchus RJ. et al. An individualized approach to the evaluation and management of primary aldosteronism. Endocr Pract 2017; 23: 680-689
39 Mulatero P, Monticone S, Deinum J. et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: A position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J Hypertens 2020; 38: 1919-1928
40 Naruse M, Katabami T, Shibata H. et al. Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr J 2022; 69: 327-359
41 Calhoun DA, Nishizaka MK, Zaman MA. et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40: 892-896
42 Mosso L, Carvajal C, González A. et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-165
43 Rossi GP, Bernini G, Caliumi C. et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300
44 Douma S, Petidis K, Doumas M. et al. Prevalence of primary hyperaldosteronism in resistant hypertension: A retrospective observational study. Lancet 2008; 371: 1921-1926
45 Galati S-J, Cheesman KC, Springer-Miller R. et al. Prevalence of primary aldosteronism in an urban hypertensive population. Endocr Pract 2016; 22: 1296-1302
46 Xu F, Gao Z, Wang G. et al. Prevalence, subtype classification, and outcomes of treatment of primary aldosteronism: A prospective study in China. Endocr Pract 2021; 27: 478-483
47 Turcu AF, Nhan W, Grigoryan S. et al. Primary aldosteronism screening rates differ with sex, race, and comorbidities. J Am Heart Assoc 2022; 11: e025952
48 Cohen JB, Cohen DL, Herman DS. et al. Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans : A retrospective cohort study. Ann Intern Med 2021; 174: 289-297
49 Ito Y, Takeda R, Karashima S. et al. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects. Hypertens Res 2011; 34: 98-102
50 Vasan RS, Evans JC, Larson MG. et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33-41
51 Hu J, Shen H, Huo P. et al. Heightened cardiovascular risk in hypertension associated with renin-independent aldosteronism versus renin-dependent aldosteronism: A collaborative study. J Am Heart Assoc 2021; 10: e023082
52 Brown JM, Robinson-Cohen C, Luque-Fernandez MA. et al. The spectrum of subclinical primary aldosteronism and incident hypertension: A cohort study. Ann Intern Med 2017; 167: 630-641
53 Burrello J, Monticone S, Losano I. et al. Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit. Hypertension 2020; 75: 1025-1033
54 Médeau V, Moreau F, Trinquart L. et al. Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: A comparison with hypertensive cases. Clin Endocrinol (Oxf) 2008; 69: 20-28
55 Tang A, Pasieka J, Kline G. Normotensive hypokalemic primary aldosteronism: How is this possible?. Endocrine Abstracts 2018; 55: P26
56 Huang Y-C, Tsai M-H, Fang Y-W. et al. Normotensive hypokalemic primary hyperaldosteronism mimicking clinical features of anorexia nervosa in a young patient. Medicine (Baltimore) 2020; 99: e20826
57 Aziz M, Bloomgarden N, Friedman N. Primary aldosteronism presenting as chronic hypokalemia in a normotensive patient. J Endocr Soc 2022; 6: A256-A257
58 Mantero F, Terzolo M, Arnaldi G. et al. A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85: 637-644
59 Bernini G, Moretti A, Argenio G. et al. Primary aldosteronism in normokalemic patients with adrenal incidentalomas. Eur J Endocrinol 2002; 146: 523-529
60 Kim HY, Kim SG, Lee KW. et al. Clinical study of adrenal incidentaloma in Korea. Korean J Intern Med 2005; 20: 303-309
61 Comlekci A, Yener S, Ertilav S. et al. Adrenal incidentaloma, clinical, metabolic, follow-up aspects: Single centre experience. Endocr 2010; 37: 40-46
62 Kim J, Bae KH, Choi YK. et al. Clinical characteristics for 348 patients with adrenal incidentaloma. Endocrinol Metab (Seoul) 2013; 28: 20-25
63 Patrova J, Jarocka I, Wahrenberg H. et al. Clinical outcomes in adrenal incidentaloma: Experience from one center. Endocr Pract 2015; 21: 870-877
64 Tabuchi Y, Otsuki M, Kasayama S. et al. Clinical and endocrinological characteristics of adrenal incidentaloma in Osaka region, Japan. Endocr J 2016; 63: 29-35
65 Stavropoulos K, Imprialos KP, Katsiki N. et al. Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. J Clin Hypertens (Greenwich) 2018; 20: 942-948
66 Jing Y, Hu J, Luo R. et al. Prevalence and characteristics of adrenal tumors in an unselected screening population: A cross-sectional study. Ann Intern Med 2022; 175: 1383-1391
67 Kmieć P, Zalewska E, Kunicka K. et al. Autonomous aldosterone secretion in patients with adrenal incidentaloma. Biomedicines 2022; 10: 3075
68 Fassnacht M, Arlt W, Bancos I. et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016; 175: G1-G34
69 Lee J-M, Kim MK, Ko S-H. et al. Clinical guidelines for the management of adrenal incidentaloma. Endocrinol Metab (Seoul) 2017; 32: 200-218
70 Whelton PK, Carey RM, Aronow WS. et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71: 1269-1324
71 Williams TA, Burrello J, Sechi LA. et al. Computed tomography and adrenal venous sampling in the diagnosis of unilateral primary aldosteronism. Hypertension 2018; 72: 641-649
72 Sam D, Kline GA, So B. et al. Discordance between imaging and adrenal vein sampling in primary aldosteronism irrespective of interpretation criteria. J Clin Endocrinol Metab 2019; 104: 1900-1906
73 Wannachalee T, Caoili E, Nanba K. et al. The concordance between imaging and adrenal vein sampling varies with aldosterone-driver somatic mutation. J Clin Endocrinol Metab 2020; 105: e3628-e3637
74 Nanba AT, Nanba K, Byrd JB. et al. Discordance between imaging and immunohistochemistry in unilateral primary aldosteronism. Clin Endocrinol (Oxf) 2017; 87: 665-672
75 Omata K, Satoh F, Morimoto R. et al. Cellular and genetic causes of idiopathic hyperaldosteronism. Hypertension 2018; 72: 874-880
76 Nishimoto K, Seki T, Hayashi Y. et al. Human adrenocortical remodeling leading to aldosterone-producing cell cluster generation. Int J Endocrinol 2016; 2016: 7834356
77 Piaditis GP, Kaltsas GA, Androulakis II. et al. High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas. Clin Endocrinol (Oxf) 2009; 71: 772-778
78 Markou A, Kaltsas GA, Papanastasiou L. et al. Enhanced performance of a modified diagnostic test of primary aldosteronism in patients with adrenal adenomas. Eur J Endocrinol 2022; 186: 265-273
79 Loh HH, Sukor N. Primary aldosteronism and obstructive sleep apnea: What do we know thus far?. Front Endocrinol (Lausanne) 2022; 13: 976979
80 Raff H, Roarty TP. Renin, ACTH, and aldosterone during acute hypercapnia and hypoxia in conscious rats. Am J Physiol 1988; 254: R431-R435
81 Di Murro A, Petramala L, Cotesta D. et al. Renin-angiotensin-aldosterone system in patients with sleep apnoea: Prevalence of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2010; 11: 165-172
82 Dobrowolski P, Kołodziejczyk-Kruk S, Warchoł-Celińska E. et al. Primary aldosteronism is highly prevalent in patients with hypertension and moderate to severe obstructive sleep apnea. J Clin Sleep Med 2021; 17: 629-637
83 Buffolo F, Li Q, Monticone S. et al. Primary aldosteronism and obstructive sleep apnea: A cross-sectional multi-ethnic study. Hypertension 2019; 74: 1532-1540
84 Kapur VK, Auckley DH, Chowdhuri S. et al. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med 2017; 13: 479-504
85 Chee MR, Hoo J, Libianto R. et al. Prospective screening for primary aldosteronism in patients with suspected obstructive sleep apnea. Hypertension 2021; 77: 2094-2103
86 Chomsky-Higgins Menut K, Pearlstein SS, Conroy PC. et al. Screening for primary aldosteronism in the hypertensive obstructive sleep apnea population is cost-saving. Surgery 2022; 171: 96-103
87 Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: When, who, and how to screen?. Eur Heart J 2014; 35: 1245-1254
88 Viera AJ, Neutze DM. Diagnosis of secondary hypertension: An age-based approach. Am Fam Physician 2010; 82: 1471-1478
89 Alam S, Kandasamy D, Goyal A. et al. High prevalence and a long delay in the diagnosis of primary aldosteronism among patients with young-onset hypertension. Clin Endocrinol (Oxf) 2021; 94: 895-903
90 Nguyen V, Tu TM, Mamauag MJB. et al. Primary aldosteronism more prevalent in patients with cardioembolic stroke and atrial fibrillation. Front Endocrinol (Lausanne) 2022; 13: 869980
91 Seccia TM, Letizia C, Muiesan ML. et al. Atrial fibrillation as presenting sign of primary aldosteronism: Results of the Prospective Appraisal on the Prevalence of Primary Aldosteronism in Hypertensive (PAPPHY) Study. J Hypertens 2020; 38: 332-339
92 McCarthy J, Yang J, Clissold B. et al. Hypertension management in stroke prevention: Time to consider primary aldosteronism. Stroke 2021; 52: e626-e634
93 Miyaji Y, Kawabata Y, Joki H. et al. Primary aldosteronism in patients with acute stroke: Prevalence and diagnosis during initial hospitalization. BMC Neurol 2016; 16: 177
94 Tyfoxylou E, Voulgaris N, Gravvanis C. et al. High prevalence of primary aldosteronism in patients with type 2 diabetes mellitus and hypertension. Biomedicines 2022; 10: 2308
95 Memon SS, Lila A, Barnabas R. et al. Prevalence of primary aldosteronism in type 2 diabetes mellitus and hypertension: A prospective study from Western India. Clin Endocrinol (Oxf) 2022; 96: 539-548
96 Manosroi W, Atthakomol P. High body fat percentage is associated with primary aldosteronism: A cross-sectional study. BMC Endocr Disord 2020; 20: 175
97 Rossi GP, Rossi E, Pavan E. et al. Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol (Oxf) 1998; 49: 713-723